Short answer

Assembly Biosciences Inc (ASMB) filed its fiscal 2011 10-K annual report with the SEC on Mar 14, 2012.

Top risk flagged: FDA SPA absent for VEN 309 Phase III trials, leaving protocol recommendations non-binding and approval uncertain

Assembly Biosciences Inc FY2011 10-K analysis

AI summary of each section, grounded in the filing text

Development-stage specialty pharma focused on topical lower-GI treatments for hemorrhoids, anal fissures and fecal incontinence
VEN 309 Phase III hemorrhoid trial launched August 2011, targeting approximately 600 patients across up to 70 U.S. sites
Strategic shift from cash-constrained inactivity to late-stage execution, funded by $17.5 million IPO proceeds and $47.5 million July offering
VEN 309 rights acquired outright from Amer on November 14, 2011, replacing prior licensing arrangement
Workforce expanded to seven employees and seven consultants, supporting Phase III development and commercialization planning

Revenue $0, unchanged YoY, no FDA-approved products or commercial sales
Net loss $34.3M, R&D expense $25.3M vs $1.9M, G&A expense $8.7M vs $2.9M
Best performer VEN 309 R&D $22.2M, worst VEN 307 R&D $1.9M
Operating cash use $25.1M, financing $47.5M, capex $11,964, no buybacks or dividends
Cash runway into third quarter 2013, additional funding needed, clinical and regulatory outcomes key risks

FDA SPA absent for VEN 309 Phase III trials, leaving protocol recommendations non-binding and approval uncertain
Foreign contract manufacturers expose clinical supply to shipping delays and import restrictions
Rectiv, FDA-approved in June 2011, expected to reach market in Q1 2012 for anal fissures
Future VEN 307, VEN 308 and VEN 309 development costs estimated at $20 million, $15 million and $40 million
VEN 307 and VEN 308 licenses face termination after payment default, including $41,500 monthly fees and $400,000 milestone payment

Generated from the filing text; verify against the original. How to read a 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.